
La Jolla Pharmaceutical Company LJPC
La Jolla Pharmaceutical Company Betriebsaufwand | LJPC
Betriebsaufwand Jährlich La Jolla Pharmaceutical Company
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 61.4 M | 130 M | 202 M | 115 M | 79 M | 43 M | 21.3 M | 17.9 M | 10.7 M | 2.27 M | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 202 M | 2.27 M | 68.4 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
31.4 M | - | - | $ 24.9 M | ||
|
Завод ДИОД
DIOD
|
249 M | - | - | - | ||
|
Фармсинтез
LIFE
|
201 M | - | - | - | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
105 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
34.4 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
308 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
136 M | - | - | $ 2.36 B | ||
|
Exicure
XCUR
|
4.23 M | $ 1.09 | 3.81 % | $ 6.86 M | ||
|
Cellectis S.A.
CLLS
|
109 M | $ 0.95 | -3.3 % | $ 95.3 M | ||
|
AbCellera Biologics
ABCL
|
292 M | $ 12.03 | 1.78 % | $ 3.59 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 58.93 | 1.57 % | $ 7.88 B | ||
|
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 55.62 | -0.59 % | $ 10.7 B | ||
|
Celldex Therapeutics
CLDX
|
58.1 M | $ 29.48 | 0.79 % | $ 1.96 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
8.73 M | $ 3.75 | 2.18 % | $ 45.8 M | ||
|
Jaguar Health
JAGX
|
36 M | $ 2.36 | 15.44 % | $ 5.5 M | ||
|
Protalix BioTherapeutics
PLX
|
54.5 M | $ 2.49 | -2.35 % | $ 196 M | ||
|
uniQure N.V.
QURE
|
128 M | $ 21.65 | -3.5 % | $ 1.24 B | ||
|
Stoke Therapeutics
STOK
|
205 M | $ 25.41 | 1.48 % | $ 1.5 B | ||
|
Xencor
XNCR
|
303 M | $ 29.2 | 15.95 % | $ 2.17 B | ||
|
Annexon
ANNX
|
216 M | $ 3.71 | -1.2 % | $ 575 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 1.71 | -4.21 % | $ 2.82 M | ||
|
Incyte Corporation
INCY
|
1.62 B | $ 113.3 | -2.08 % | $ 22.1 B | ||
|
Mesoblast Limited
MESO
|
86.7 M | $ 12.43 | 1.22 % | $ 15 B | ||
|
MeiraGTx Holdings plc
MGTX
|
187 M | $ 9.2 | -0.16 % | $ 740 M | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
2.41 B | $ 516.39 | -1.44 % | $ 132 B | ||
|
Burford Capital Limited
BUR
|
181 M | $ 3.24 | -3.72 % | $ 710 M | ||
|
Catalyst Biosciences
CBIO
|
105 M | $ 12.77 | -0.39 % | $ 1.14 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 25.47 | 1.29 % | $ 1.19 B | ||
|
Anika Therapeutics
ANIK
|
51.6 M | $ 21.19 | -1.07 % | $ 304 M | ||
|
Editas Medicine
EDIT
|
201 M | $ 2.4 | 0.05 % | $ 213 M | ||
|
Evogene Ltd.
EVGN
|
13.8 M | $ 0.37 | 0.44 % | $ 2.91 M | ||
|
EyePoint Pharmaceuticals
EYPT
|
275 M | $ 0.36 | -10.09 % | $ 26.4 K | ||
|
Fortress Biotech
FBIO
|
125 M | $ 1.87 | -3.11 % | $ 52.2 M | ||
|
Fennec Pharmaceuticals
FENC
|
50.9 M | $ 10.12 | 0.4 % | $ 289 M | ||
|
Foghorn Therapeutics
FHTX
|
117 M | $ 2.04 | 2.0 % | $ 128 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
119 B | $ 13.76 | 4.13 % | $ 11.5 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 9.91 | 0.71 % | $ 271 M | ||
|
Sanofi
SNY
|
27.3 B | $ 41.77 | 0.41 % | $ 51 B | ||
|
Arcutis Biotherapeutics
ARQT
|
305 M | $ 31.74 | 1.73 % | $ 4.04 B | ||
|
Geron Corporation
GERN
|
252 M | $ 1.15 | 2.23 % | $ 767 M | ||
|
Gossamer Bio
GOSS
|
219 M | $ 9.2 | -4.27 % | $ 2.1 B | ||
|
Titan Pharmaceuticals
TTNP
|
4.56 M | - | -3.76 % | $ 3.47 M | ||
|
Allena Pharmaceuticals
ALNA
|
10.1 M | - | 3.16 % | $ 1.9 M |